Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;11(2):253-274.
doi: 10.3233/JND-230189.

The Importance of Early Treatment of Inherited Neuromuscular Conditions

Laurane Mackels  1   2 , Laurent Servais  3   4
Affiliations
Review

The Importance of Early Treatment of Inherited Neuromuscular Conditions

Laurane Mackels et al. J Neuromuscul Dis. 2024.

Abstract

There has been tremendous progress in treatment of neuromuscular diseases over the last 20 years, which has transformed the natural history of these severely debilitating conditions. Although the factors that determine the response to therapy are many and in some instance remain to be fully elucidated, early treatment clearly has a major impact on patient outcomes across a number of inherited neuromuscular conditions. To improve patient care and outcomes, clinicians should be aware of neuromuscular conditions that require prompt treatment initiation. This review describes data that underscore the importance of early treatment of children with inherited neuromuscular conditions with an emphasis on data resulting from newborn screening efforts.

Keywords: Inherited neuromuscular conditions; children; early treatment; newborn screening; timely treatment.

PubMed Disclaimer

References

    1. Wirth B, Garbes L, Riessland M. How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches. Current opinion in genetics & development. 2013;23(3):330–8. - PubMed
    1. Tasfaout H, et al.. Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice. Nat Commun. 2017;8(1):15661–15661. - PMC - PubMed
    1. Fisher G, et al.. Early clinical and pre-clinical therapy development in Nemaline myopathy. Expert Opinion On Therapeutic Targets. 2022;26(10):853–67. - PubMed
    1. Estepan ISarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy| Sarepta Therapeutics. Inc. Investorrelations, 2019.
    1. Mendell JR, et al.. Limb-girdle muscular dystrophy type 2D gene therapy restores α-sarcoglycan and associated proteins. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2009;66(3):290–7. - PMC - PubMed